IRD7:00 AMOpus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate UpdateTrial Results • Phase 1/2OPGx-BEST1 Cohort 1 topline data Sun, Sep 6, 2026, 7:00 AM EDTGopusgtx.com
IRD7:00 AMOpus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseEnrollment • Phase 3Enrollment milestone Mon, Aug 3, 2026, 7:00 AM EDTGopusgtx.com
IRD7:00 AMOpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 ResultsTrial Results • Phase 1/2Cohort 1 topline data Wed, Sep 9, 2026, 7:00 AM EDTGopusgtx.com
IRD7:00 AMOpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseTrial Design Update • Phase 3Trial update Mon, Jul 6, 2026, 7:00 AM EDTGopusgtx.com
IRD9:15 AMOpus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexesopusgtx.com
IRD4:05 PMOpus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal DiseasesTrial Results • Phase 1/2Topline data Tue, Sep 1, 2026, 4:05 PM EDTGopusgtx.com
IRD7:00 AMOpus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease ExpertsResults CallResults call Tue, Jun 16, 2026, 10:00 AM ETGopusgtx.com